Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-protozoal compounds and uses thereof

a technology of protozoal compounds and compounds, applied in the field of veterinary formulations, can solve the problems of significant impact on the breeding herd, endometritis, cervicitis, vaginitis, etc., and achieve the effect of improving administration and treatment, and reducing the risk of infection in the breeding herd

Pending Publication Date: 2022-01-13
AUBURN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present patent provides veterinary formulations and methods for treating trichomoniasis and T. foetus infections in cattle through the use of antiprotozoal compounds that are safe for food-producing animals and have known withdrawal times. The formulations are designed to effectively disrupt the lipid layer of the stratum corneum, allowing the therapeutic agents to pass through and eradicate infectious organisms with no reemergence of trophozoites or pseudocysts. These formulations have shown promising results in treating cattle with trichomoniasis and T. foetus infections and provide an improved method for administering and treating these infections in cattle.

Problems solved by technology

In cows, the disease is typically self-limiting, as the infection is commonly cleared in a few months after several heat cycles.
Trichomoniasis can cause significant impacts to a breeding herd.
Infection in cows can result in endometritis, cervicitis, and vaginitis.
In addition to reproductive impacts, trichomoniasis can cause significant economic losses for both beef and dairy cattle producers.
If the losses are extended to the feedlot / finishing producers, the loss increases to over S150 million.
Including the impacts of secondary and indirect losses, trichomoniasis is estimated to cost the industry approximately S300 million annually.
However, the vaccine (TrichGuard) does not provide protection from infection with T. foetus and, instead, only reduces shedding of T. foetus organisms.
Although vaccination programs can decrease the severity of clinical signs, they are unable to completely prevent abortion within a herd.
Moreover, an approved therapeutic option is not available for cows or bulls infected with T. foetus.
With the lack of an effective FDA approved treatment, current recommendations are labor intensive and costly as infected bulls must be slaughtered.
Although annual testing is recommended in bulls, there is a lack of sensitivity of the screening tests, which could still result in infection in the herd.
Second, the veterinary formulations comprise a polymer for drug delivery that effectively disrupts the lipid layer of the stratum corneum, allowing therapeutic agents to pass through the stratum corneum and into the systemic circulation via the dermal-epidermal blood flow.
Third, the veterinary formulations can result in complete eradication of infectious organisms with no reemergence of trophozoites or pseudocysts, and with cultures remaining negative, for several days following administration.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-protozoal compounds and uses thereof
  • Anti-protozoal compounds and uses thereof
  • Anti-protozoal compounds and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0163]Trophozoites (3.75×105 mL−1) were washed in PBS (VWR, Radnor, Pa.) and inoculated into 10 mL of fresh DM. At time 0, each of the following treatment groups was added to culture tubes: Group 1) control: 0.5 mL DM; Group 2) 0.5 mL pluronic lecithin organogel (PLO; Pluronic F127); Group 3) 75 mg ponazuril (PO) (0.5 mL); Group 4) 50 mg oxibendazole (OX) (0.5 mL); Group 5) 37.5 mg PO (0.25 mL)+0.25 mL PLO; and Group 6) 25 mg OX (0.25 mL)+0.25 mL PLO.

[0164]PLO (Pluronic F127 Letco Medical, Decatur, Ala.) was combined with OX (Anthelcide EQ® Zoetis, Florham Park, N.J.) or PO (Marquis® Merial, Duluth, Ga.) paste formulations by shear force, syringe-to-syringe-blending using two luer-lock syringes and a rapid fill connector (Baxter, Inglewood, Calif.). Each treatment was applied to conical culture tubes in 5 replicates. Following growth at 37° C., samples were taken every 2 hours for a total of 12 hours, and the tubes were vortexed prior to removal of a 20 μL sample. From these samples...

example 2

[0167]Trophozoites (9.5×105 mL−1) were cultured as described above and added to tissue culture wells with 3 mL of DM. At time 0, each of the following treatment groups were added to tissue culture wells: Group 1) control 4 mL DM; Group 2) 4 mL PLO; Group 3) 150 mg oxfendazole (OXF)+1 mL PLO; and Group 4) 450 mg PO (3 mL)+1 mL PLO.

[0168]The OXF (U.S. Pharmacopeial Convention Rockville, Md.) stock solution was made in EtOH (Humco Texarkana, TX) and mixed with Velvachol (“VC”; Valeant North America LLC, Bridgewater, N.J.) and thereafter was stored at 150 mg mL−1. PLO was combined with OXF stock solution or PO by shear force by syringe-to-syringe mixing. Each treatment was applied to tissue culture wells in duplicate. Following growth at 37° C. on a rocker plate (Hoefer Inc., Holliston, Mass.), samples were collected every 4 hours for a total of 24 hours. A 20 μL sample was removed from each well, and the surviving organisms were counted utilizing disposable Neubauer hemocytometers.

[016...

example 3

[0171]Trophozoites (5×104 mL−1) were cultured as described above and added to all tissue culture wells along with 3 mL of DM for a total volume of 4 mL of DM with 50,000 organisms per well. At time 0, each of the following treatment groups were added to tissue culture wells as follows: Group 1) positive control 4 mL DM; Group 2) negative control 4 mL 70% ethanol (EtOH); Group 3) 150 mg oxfendazole solution (OXF) (1 mL)+2 mL Velvachol (VC)+1 mL PLO; Group 4) 150 mg OXF (1 mL)+3 mL VC; Group 5) 150 mg OXF (1 mL)+3 mL EtOH; Group 6) 150 mg OXF (1 mL)+2 mL EtOH+1 mL PLO; Group 7) 1 mL EtOH+2 mL VC+1 mL PLO; Group 8) 1 mL EtOH+3 mL VC; Group 9) 3 mL EtOH+1 mL PLO; Group 10) 4 mL EtOH; Group 11) 4 mL VC; Group 12) 150 mg oxfendazole dissolved in 4 mL 99% DMSO; and Group 13) 4 mL 99% DMSO.

[0172]The OXF (U.S. Pharmacopeial Convention Rockville, Md.) stock solution was made in EtOH (Humco Texarkana, TX) and stored at 150 mg mL−1, with the exception of Formulation 13 which included OXF dissol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure provides veterinary formulations comprising a therapeutically effective amount of an antiprotozoal compound and a polymer. The disclosure also provides methods of treating trichomoniasis in a bovine and methods of treating a Tritrichomonas foetus infection in a bovine utilizing the veterinary formulations.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit under 35 USC § 119(e) of U.S. Provisional Application Ser. No. 62 / 504,721, filed on May 11, 2017, the entire disclosure of which is incorporated herein by reference.TECHNICAL FIELD[0002]The invention relates to veterinary formulations comprising a therapeutically effective amount of an antiprotozoal compound and a polymer. The invention includes compositions, methods, and formulations for the treatment of disease, such as for treating trichomoniasis in a bovine.BACKGROUND AND SUMMARY OF THE INVENTION[0003]Trichomoniasis is a sexually transmitted disease in cattle that is caused by the protozoa Tritrichomonas foetus. The organism is a single-celled, flagellated parasite that colonizes the epithelial crypts of the preputial mucosa in the preputial folds of bulls. Infected bulls are unaffected carriers of the organism, while cows can become infected during breeding. In cows, the disease is typically self-l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K47/34A61K31/53A61P33/02A61K9/00A61K31/4184
CPCA61K47/34A61K31/53A61K31/4184A61K9/0034A61P33/02
Inventor DURAN, SUE H.
Owner AUBURN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com